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ABSTRACT
The COVID-19 restrictions affect daily living in Norway, including home-dwelling people with
dementia, and researchers conducting clinical trials in dementia care. In this paper, we 1)
describe the development of a pandemic cohort (PAN.DEM) incorporated in the
LIVE@Home.Path, an ongoing clinical intervention trial on resource utilisation including home-
dwelling people with dementia and their caregivers (N¼ 438 dyads), 2) describe pre-pandemic
use of assistive technology and 3) explore the extent to which COVID-19 restrictions increase
caregivers interest in innovation in the PAN.DEM cohort (N¼ 126). Our main finding is that
assistive technology is available to 71% pre-pandemic; the vast majority utilise traditional stove
guards and safety alarms, only a few operate sensor technology, including GPS, fall detectors or
communication aids. In response to COVID-19, 17% show increased interest in technology; being
less familiar with operating a telephone and having higher cognitive functioning are both asso-
ciated with increased interest. We conclude that wearable and sensor technology has not yet
been fully implemented among people with dementia in Norway, and few caregivers show
increased interest under the restrictions.
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In response to the COVID-19 pandemic, the
Norwegian government on 12 March 2020 announced
the most severe and restrictive measures ever imple-
mented in peacetime. In the municipalities, 900 nurs-
ing homes were closed to visitors, a restriction that
very likely protected many lives (Islam et al., 2020),
while healthcare personnel were redirected from
dementia teams and homecare services to more care-
intensive functions such as nursing home wards.
Those still working in homecare were limited to see-
ing only the most vulnerable patients for the shortest
possible time, and caregivers were encouraged to
refrain as much as possible from physical contact. At
the same time, concerns rose about the deterioration
of daily functioning among home-dwelling people
with dementia, as the threat of isolation and disrup-
tion of day-to-day routines may increase loneliness,
depressive symptoms and risk of adverse events
(Husebo & Berge, 2020).
At the time of writing (20 September 2020),
Norway is approaching the second COVID-19 peak.
Stakeholders, clinicians and politicians need tools to
minimise the harmful effects of social distancing and
isolation at home. A wide array of new technologies
may provide solutions (Yang & Kels, 2017). Our cur-
rent review presents existing research on commer-
cially available and prototype technologies that utilise
wearable sensors, nonwearable motion sensor technol-
ogies, and assistive technologies/smart housing
(Husebo et al., 2019). Different prognostic approaches
at home may have the potential to inform clinicians
about a range of patient responses, including
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alterations in circadian rhythm (Merilahti et al.,
2016), changes in gait speed (Channa et al., 2020),
falls (Silva de Lima et al., 2017), and monitoring
behaviour such as agitation and wandering (Khan
et al., 2018; Kernebeck et al., 2019; Bankole et al.,
2020). Further, devices for better communication (on
behalf of the PD_Manager consortium, 2018; Dorsey
et al., 2020), ethical considerations of surveillance
technology in dementia (Sorell & Draper, 2012), or
the need for real-world, evidence-based solutions to
conduct clinical trials (Teipel et al., 2018) are becom-
ing potentially available.
Nevertheless, barriers to the implementation of
technology for home-dwelling elderly exist, including
governmental engagement, industry resources and
competence, home-care services awareness, patients’
mental state, and relatives’ attitude (Holthe et al.,
2020). To learn more about innovation at home, we
initiated the LIVE@Home.Path, a 2-year, multicompo-
nent, stepped-wedge intervention trial for people with
dementia and their caregivers (Husebo et al., 2020).
One important outcome is the implementation of and
experience with assistive technology.
In this study, we present a real-time snapshot of
access to assistive technology in this population before
and during the COVID-19 pandemic. We use data
from PAN.DEM (PANdemic in DEMentia) a study of
the LIVE@Home.Path trial to a) investigate the pre-
pandemic access to assistive technology among home-
dwelling people with dementia; b) explore whether
COVID-19 restrictions increased caregivers’ interest
in assistive technology, and possible factors associated
with increased interest, and c) discuss safety proce-
dures to adapt the ongoing LIVE@Home.Path trial to
the pandemic scenario, in accordance with the princi-
ples of responsible research innovation (RRI) (Schuijff
& Dijkstra, 2020).
Method
The study protocol of the LIVE@Home.Path describes
the multicomponent, randomised controlled design
including home-dwelling people with dementia and
their informal caregivers, constituting a dyad (Husebo
et al., 2020). Participants were eligible for inclusion
from May 2019 if they were 65 years, diagnosed
with dementia according to a standardised protocol,
Mini-Mental Status Examination (MMSE) score
15–26 or Functional Assessment Scaling (FAST) score
3–7 (Folstein et al., 1975; Reisberg, 1988). The
stepped-wedge randomisation implies that all partici-
pants will receive the six-month intervention
consisting of Learning; Innovation; Volunteerism, and
Empowerment delivered by a municipal coordinator,
while the timing is determined by randomisation. The
participants waiting for the intervention constitute the
control group (Figure 1).
Primary and secondary outcomes
The researchers and coordinators assess data in direct
conversation with the person with dementia and the
caregivers. According to the mixed method design
(John, 2011), core outcomes will be explored using
both qualitative and quantitative data. The primary
outcome is resource utilisation in terms of formal and
informal care time, as measured by the Resource
Utilisation in Dementia (RUD) instrument(Wimo
et al., 2013; Wimo et al., 2010) and the Relative Stress
Scale (RSS) (Greene et al., 1982), while secondary out-
comes, amongst others, are successful implementation
and utilisation of assistive technology. Other second-
ary outcomes are shown in Table 1 (Naglie et al.,
2006; Whynes & Group, 2008; Hoe et al., 2005;
Husebo et al., 2014; Guy, 1976; Rabinowitz et al.,
2005; Cummings, 2020; Alexopoulos et al., 1988;
Yesavage et al., 1982; Lawton, 1990; Lawton & Brody,
1969; Lyketsos et al., 1999).
Process development of LIVE@Home.Path under
the COVID-19 restrictions
By the end of February 2020, the first group of dyads
had completed the six-month LIVE-intervention, and
the second group was scheduled to receive the inter-
vention from March to August 2020. During the
COVID-19 lockdown, the intervention protocol was
temporarily halted and replaced with PAN.DEM, a
nested cohort study within the LIVE@Home.Path.
Data were collected by semi structured telephone
interviews with caregivers assessing how the pandemic
scenario affected the dyads in terms of resource and
service utilisation. The interdisciplinary research
group revised the PAN.DEM assessment after 6–8
interviews. The final version is found in the supple-
mentary enclosure, while outcome measures are
shown in Table 1. Furthermore, research procedures
for the LIVE@Home.Path trial were revised to ensure
minimal risk of viral transmission, adapted to periods
of both high risk (remote contact via telephone only)
and low risk of transmission (possibility of home vis-
its according to the participants’ wishes) (Table 2).
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Statistics
We used descriptive statistics to explore the distribu-
tion of pre-pandemic characteristics of the person
with dementia and their caregiver, in addition to the
frequency of access to any assistive technology.
Logistic regression was applied to explore factors
associated with increased interest in assistive technol-
ogy under the COVID-19 restrictions, and estimates
were presented as odds rations (OR) with 95%
Table 1. Outcome measures in the LIVE@Home.Path trial and the PAN.DEM study.
LIVE@Home.Path PAN.DEM
PAN.DEM assessment x
Resource Utilisation in Dementia (RUD) (Wimo et al., 2013; Wimo et al., 2010) x x
Relative Stress Scale (RSS) (Greene et al., 1982) x
European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) (Naglie et al., 2006) x
EQ-5D-VAS Scale (Whynes & Group, 2008) x
Quality of Life In Alzheimers Disease Scale (QOL-AD) (Hoe et al., 2005) x
Mobilization-Observation-Behaviour-Intensity Dementia Pain Scale (MOBID-2 Pain Scale) (Husebo et al., 2014) x
Clinical Global Impression of Change (CGIC) (Guy, 1976) x x
Cohen-Mansfield Agitation Inventory (CMAI) (Rabinowitz et al., 2005) x
Neuropsychiatric Inventory, 12 Item version (NPI-12) (Cummings, 2020) x x
Cornell Scale for Depression in Dementia (CSDD) (Alexopoulos et al., 1988) x x
Geriatric Depression Scale (GDS) (Yesavage et al., 1982) x
Activities of Daily Living, Instrumental (I-ADL) (Lawton, 1990; Lawton & Brody, 1969) x
Activities of Daily Living, Personal (PSMS) (Lawton, 1990; Lawton & Brody, 1969) x
General Medical Health Rating Scale (GMRH) (Lyketsos et al., 1999) x
Figure 1. Flow chart of participants in the LIVE@Home.Path trial and the PAN.DEM study.
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confidence intervals. We applied Akaikes information
criterion for model selection; level of significance was
set to p Value < 0.05. Stata/IC, release 16 (StataCorp
LP, College Station, TX) was used to analyse the data.
Ethics
All participants in the LIVE@Home.Path provided
verbal and written informed consent for participation.
At inclusion in PAN.DEM, verbal consent was
obtained from the caregivers after verbal and written
information was provided. If the person with demen-
tia was evaluated as incapable of providing informed
consent, the next of kin or legal advocate provided
presumed consent based on their determination of
whether the person would have agreed to participate
when they were capable of providing informed con-
sent. The LIVE@Home.Path trial and the PAN.DEM
study were both approved by the Regional Committee
for Medical and Health Research Ethics, North
Norway prior to data collection, reference 2019/385
and sub reference 10861.
Results
A total of 281 dyads were included to the
LIVE@Home.Path trial, 237 dyads were active in the
trial at the beginning of March 2020, of which 126
were consecutively included to the PAN.DEM by a
phone call invitation (Figure 1). Table 3 presents
descriptive statistics on the participating dyads in
PAN.DEM. Mean age for the person with dementia
was 82 years; 61% were women, and 40% lived alone.
A total of 71% of the participants had access to
some assistive technology before the COVID-19
restrictions (Table 4). The majority used traditional
appliances such as safety alarms and stove guards,
while few had any kind of sensor technology; includ-
ing GPS, fall detector, and medication adherence
support. According to IADL, 15% were fully inde-
pendent in using the telephone, including looking up
telephone numbers and making calls, while 54% were
able to call a few, well-known numbers. Use of social
media was rare among persons with dementia; two
used Facebook including Messenger; one person com-
municated with Skype.
During the COVID-19 restrictions, 14% of the
caregivers reported more digital contact with the per-
son with dementia compared with pre-pandemic con-
ditions, while 17% reported increased interest in
assistive technology (Table 5). Caregivers reported
lack of insight to the COVID-19 pandemic in major-
ity of cases; 50% had partial insight and 15% no
insight. Caregivers for people with higher scores on
the MMSE (OR 1.26, 95% CI 1.03–1.54, p¼ 0.032)
and less familiarity with using the telephone assessed
by IADL (OR 2.60, 95% CI 1.08–6.23, p¼ 0.032) were
more likely to report increased interest in technology
under the pandemic. The insight of the person with
dementia into the COVID-19 situation, the change in
level of contact with caregiver, depressive symptoms
during the pandemic, the level of function assessed by
FAST, dementia aetiology, health evaluated by
Table 2. Revised procedures for data collection and imple-
mentation of the LIVE@Home.Path trial to comply with the
COVID-19 restrictions.
 Immediately before study home visits, make a phone call to evaluate
participants’ physical status, including any respiratory symptoms or
fever, contacts with COVID-19 positive individuals, or travel abroad
during the last 14 days.
 In the event of symptoms of infections in the respiratory organs, the
researchers or other study personnel must not carry out travel
activities or home visits.
 Good hand hygiene is a key preventive measure at all risk points,
such as travel and home visits. Study personnel must make sure to
bring their own hand sanitiser.
 When travelling is required, avoid rush hour, and/or use a taxi or car
rental service rather than public transport.
Table 3. Pre-pandemic characteristics for the PAN.DEM
dyads (N¼ 126).
n (%) mean (SD)
People with dementia
Age 82 (6.95)
Sex, Female 77 (61)
Residency
Living alone 51 (40)
Co-residing with the reporting caregiver 55 (44)
Co-residing with someone else 16 (13)
Dementia aetiology per ICD-10
Alzheimer’s Disease 49 (39)
Vascular Dementia 6 (5)
Dementia in other diseases classified elsewhere 11 (9)
Unspecified Dementia 58 (46)
GMHR, range 1-4 2.72 (0.70)
MMSE, range 0-30 20.85 (3.91)
FAST, range 1-7 4.08 (0.80)
CSDD total score, range 0-38 6.50 (5.41)
Caregiver
Age 66 (12.35)





n: number of participants. SD: standard deviation.
ICD-10: the International Statistical Classification of Diseases and Related
Health Problems.
GMHR (Lyketsos et al., 1999): General Medical Health Rating Scale; 1–
poor, 2 – moderate; 3 – good, 4 – excellent health.
MMSE (Folstein et al., 1975): Mini-Mental Status Examination; high score
indicates high level of cognitive functioning.
FAST (Reisberg, 1988): Functional Assessment Scaling; high score indicates
high functional impairment.
CSDD (Alexopoulos et al., 1988): Cornell Scale of Depression in Dementia;
higher score indicates depression of increasing severity.
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GMHR, access to assistive technology, and demo-
graphic variables were not associated with increased
interest (data not shown). Use of social media was
not included in the regression analysis due to the low
frequency of use.
Discussion
The PAN.DEM study was developed as a response to
the COVID-19 restrictions in Norway, aiming to
explore how the lockdown affected home-dwelling
people with dementia and their caregivers.
Prerequisites for continuing research during the
restrictions included changes in procedures for
data collection, changes in the types of data that
could be obtained, and considerable flexibility of
both the participants and the research team to meet
each other in the new context. While pausing the
LIVE@Home.Path, we were thus able to explore con-
sequences of the ongoing societal changes, a major
strength of the study, although limited to a sample of
less than half of the dyads still in the trial.
Pre-pandemic access to assistive technology was
identified among 71% of people with dementia.
However, the vast majority had access to traditional
technology such as safety alarms and stove guards,
Table 4. Pre-pandemic access to assistive technology and social media for the PAN.DEM dyads (N¼ 126).
n (%)
Access to assistive technology 88 (71)
Number of assistive technology devices implemented, mean (SD) 1.48 (1.61)
Safety, nonwearables (not exclusive items) 57 (45)
Door sensor 3 (2)
Door camera 1 (1)
Electric door lock 16 (13)
Water sensor 1 (1)
Light sensor 0 (0)
Bed sensor 2 (2)
Timer on electric devices 13 (13)
Stove guard 46 (37)
Safety, wearables (not exclusive items) 48 (38)
Safety alarm without GPS 43 (35)
Safety alarm with GPS 2 (2)
GPS 3 (2)
Fall sensor 0 (0)
Communication devices, e.g. “KOMP” 0 (0)
Orienting devices (not exclusive items) 45 (36)
Calendar to plan or keep track of the time of day, e.g. “MEMOday” 43 (34)
Automatic drug dispensers, e.g. “Pilly” and multi-dose drug dispensing robots 8 (6)
Ability to operate telephone per IADL
Operates telephone on own initiative, looks up and dials numbers 18 (15)
Dials a few well-known numbers 66 (54)
Answers telephones, but does not dial 24 (20)
Does not use telephone at all 14 (11)




n: number of participants. SD: standard deviation.
IADL (Lawton, 1990, Lawton, 1969): Activities of daily living, instrumental.
Table 5. Pandemic characteristics for the PAN.DEM dyads (N¼ 126).
n (%)
Increased interest in assistive technology due to the restrictions 21 (17)
Change in contact between within the dyad due to COVID-19 restrictions (not exclusive items)
No contact/reduced 34 (27)
More digital contact 18 (14)
Unaltered 61 (48)
Increased 27 (21)
People with dementia’s insight into the COVID-19 situation
Sufficient 44 (35)
Partial 63 (50)
To no degree 19 (15)
CGIC: Caregiver total situation, range 5-5, mean (SD) 1.85 (1.97)
n: number of participants.
CGIC (Guy, 1976): Clinical Global Impression of Change Scale; negative score – worsening, positive scores – improvement.
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while only a few could operate more novel sensor
technologies. Despite the vast potential for these
applications, we found that caregivers’ interest in new
technology increased among a minority during the
pandemic restrictions, suggesting that caregivers
might be more likely to consider technology as on
obstacle rather than a tool for independence in adapt-
ing to the pandemic situation. Our results are of key
importance for all levels and actors in the healthcare
system and the society in general; although technical
solutions are readily available, they are infrequently
implemented and accessed. This finding highlights a
great potential for initiating technology in dementia
care and research for improved resource utilisation.
To investigate the acceptability of technology,
Contreras-Somoza et al. (2020) introduce findings
from the EhcoButler trial, intended to improve health,
independence and quality of life in people with
dementia (Contreras-Somoza et al., 2020). Although
participants found the platform interesting and ergo-
nomic, researchers concluded that effective implemen-
tation depends on bridging digital gaps and requires
appropriate investment in product development
aimed at people with dementia. In Norway, the
Technology Program in Community Health Care
(2013–2016) initiated municipal small-scale studies, to
kick-start implementation of assistive technology (The
Norwegian Directorate of Health 2012). These pilots
demonstrate improved economic cost-effectiveness
and enhanced quality of services for elderly at home,
for relatives and staff (The Norwegian Directorate of
Health, 2015). Meanwhile, Holthe et al. (2020) inter-
viewed municipal healthcare professionals on their
experiences and current practice, stressing the poten-
tial of, but also the barriers to technology imple-
mented for people with dementia (Holthe et al.,
2020). This is thought-provoking because other peo-
ple with neurological diseases, such as Parkinson,
have already been utilising wearable and sensory tech-
nology as well as communication devices in recent
years (Dorsey et al., 2020). Although technology is
not a solution to all challenges, advantages may be
summarised by the 5 C’s: accessible care, increased
convenience, enhanced comfort, greater confidential-
ity for patients and families, and now reduced risk of
contagion (Dorsey et al., 2020).
The development of PAN.DEM in the
LIVE@Home.Path illustrates the importance of flex-
ible trial management for high risk populations dur-
ing the period of COVID-19, highlighting our
obligation to preserve the integrity of clinical research
activities yet minimising risks to vulnerable
participants (Brown et al., 2020; Nicol et al., 2020;
McDermott & Newman, 2020). Our adaptation and
protocol adjustment correspond with the principles of
responsible research innovation (Schuijff & Dijkstra,
2020), producing unique data providing information
on how the extraordinary pandemic restrictions
affected the everyday life of home-dwelling persons
with dementia and their informal caregivers
in Norway.
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